In line with these data, recently in a small study, the 11BHSD1 inhibitor S-707106 demonstrated an effective insulin sensitizer, anti-sarcopenic and anti-obesity effect in both Cushing’s syndrome and mHC patients [108,109,110,111,112,113]. Here, INS is linked to obesity disorder.